Cure Pharmaceutical

What Cure Pharmaceutical does

Cure Pharmaceutical is a US-based specialty pharmaceutical and bioscience company developing and commercializing CUREFilm®, a patent-protected oral thin-film drug delivery platform. The technology enables sublingual and buccal administration of actives up to 200 mg, bypassing first-pass metabolism for improved bioavailability, room-temperature stability without refrigeration, and rapid absorption versus traditional oral solids. The company is headquartered in Oxnard, California, in an FDA-registered, cGMP-certified 25,000 sqft manufacturing facility, with additional offices in Sarasota, Florida, and a CUREX regional subsidiary in Mexico City.

The company's product portfolio spans five therapeutic verticals: CUREfilm® Blue (sildenafil citrate) for erectile dysfunction; an oral thin-film insulin candidate for diabetes; CUREfilm® Compound CU-2025g for weight management; an oral hepatitis B vaccine candidate; and marketed nutraceutical SKUs sold through Target, Walgreens, and GNC. Its intellectual property estate includes 37-43 issued and pending US patents covering the delivery platform and individual product formulations.

Cure operates a hybrid B2B revenue model combining contract pharmaceutical development and manufacturing services, technology licensing of the CUREFilm® platform to pharma partners for product reformulation, and proprietary product commercialization through licensing or direct partnerships. GTM motion is primarily enterprise field sales and OEM/embedded licensing. Cure trades on OTC pink sheets (otcpink:CURR) and has executed several strategic transactions, including acquisitions of Sera Labs (2020) and Chemistry Holdings (2019), and a 2022 divestiture of legacy pharmaceutical assets for $20 million.

Name

Cure Pharmaceutical

Legal name

Cure Pharmaceutical

Website

https://curepharmaceutical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Cure Pharmaceutical is a US specialty pharmaceutical firm that develops and licenses CUREFilm®, a patent-protected oral thin-film drug delivery platform, serving pharmaceutical partners and end patients across ED, diabetes, weight management, vaccines, and nutraceuticals.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Delivery Technology

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Oral thin film drug delivery
• Sublingual pharmaceutical technology
• Pharmaceutical contract manufacturing
• Transmucosal drug delivery platforms
• CGMP pharmaceutical production

Headquarters

HQ city

Oxnard

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Development & Manufacturing Services: Cure provides contract development and manufacturing services for pharmaceutical products using its CUREFilm® platform, partnering with other pharma companies to develop products enhanced with its drug delivery technology.
2. Proprietary Product Licensing & Commercialization: Development and commercialization of proprietary products (ED, diabetes, weight management, vaccines, nutraceuticals) using CUREFilm® technology, potentially through licensing agreements or direct market entry.
3. Technology Licensing: Licensing of CUREFilm® drug delivery platform to pharmaceutical companies seeking to improve absorption, bioavailability, and patient compliance of their existing or new molecules.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Core offering

Cure Pharmaceutical develops and manufactures CUREfilm®, a patent-protected oral thin film (sublingual and buccal) drug delivery platform that enables pharmaceuticals, vaccines, and nutraceuticals to be absorbed directly into the bloodstream while bypassing first-pass metabolism. The company licenses the platform to pharmaceutical partners, performs contract development and manufacturing at its FDA-registered cGMP facility, and markets proprietary products in erectile dysfunction, diabetes, weight management, vaccines, and nutraceuticals.

Product overview

Cure Pharmaceutical operates as a drug delivery technology company offering the CUREfilm® platform as its core product—a patent-protected oral thin film technology for sublingual and buccal delivery. The platform enables pharmaceuticals, vaccines, and nutraceuticals to be delivered as thin films that dissolve rapidly in the mouth, bypassing first-pass metabolism. The company has developed specific product formulations including CUREfilm® Blue (Sildenafil Citrate) for erectile dysfunction, CUREfilm® Oral Thin Film Insulin for diabetes management, CUREfilm® Compound CU-2025g for weight management, and an Oral Hepatitis B Vaccine. The company also markets finished nutraceutical products through major retail channels. All products leverage the CUREfilm® technology to improve patient compliance, eliminate the need for injections, and provide more convenient medication administration.

Differentiator

Problem solved

Functional benefit

Brands

• CUREfilm®: Proprietary oral thin film drug delivery technology enabling sublingual and buccal delivery of pharmaceuticals, vaccines, and nutraceuticals with rapid absorption and improved bioavailability

Products and services

• CUREfilm® Oral Thin Film Drug Delivery Platform A patented oral thin film drug delivery platform that enables sublingual and buccal delivery of pharmaceuticals, vaccines, and nutraceuticals, allowing rapid absorption directly into the bloodstream while avoiding first-pass metabolism. License, contract development, and contract manufacturing are offered to pharmaceutical partners, and proprietary products are built on the platform by Cure.
• CUREfilm® Blue (Sildenafil Citrate) Patent-protected oral thin film formulation for erectile dysfunction treatment that rapidly dissolves and enters the bloodstream faster than traditional pills, offering more discreet and spontaneous use with fewer side effects for adult men with ED.
• CUREfilm® Oral Thin Film Insulin Injection-free oral thin film insulin delivery system designed to address the pain, inconvenience, and cold chain requirements of traditional insulin administration. Stable at room temperature, eliminating the need for refrigeration during storage and transport in underserved markets.
• CUREfilm® Compound CU-2025g (Weight Management) Oral thin film compound for weight management applications using the CUREfilm® platform, targeting the underserved obesity treatment population with improved bioavailability and convenience compared to standard oral anti-obesity medications.
• Oral Hepatitis B Vaccine (CUREfilm®) Oral vaccine candidate for hepatitis B delivered via the CUREfilm® oral thin film platform, intended to eliminate injection-related barriers and improve access in developing regions.
• CUREfilm®-based Nutraceuticals Marketed nutraceutical/dietary supplement products utilizing the CUREfilm® oral thin film format, available through mainstream US retail outlets including Target, Walgreens, and GNC, offering improved absorption and convenience versus standard tablets or capsules.

Quantifiable outcome

• Eliminates first-pass metabolism, improving bioavailability of drugs
• +3 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• CUREXOthersCUREX is a subsidiary of Cure Pharmaceutical located in Mexico City, handling regional operations, distribution, and partnerships within Latin American markets including Mexico and potentially broader Spanish-speaking regions.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Aquestive Therapeutics: Direct oral thin-film drug delivery competitor with FDA-approved products (Zuplenz, Exservan, Sympazan) and a similar licensing-plus-proprietary-product business model targeting CNS and other therapeutic areas.
• IntelGenx Technologies: Oral thin-film drug delivery company using its VersaFilm® platform to develop and license reformulated molecules, competing head-to-head with CUREFilm® for pharmaceutical partner licensing deals.
• Tapemark: Contract manufacturer specializing in transdermal patches and oral thin films for pharmaceutical partners, offering a similar end-to-end development and cGMP manufacturing service model.
• ZIM Laboratories: Specialty pharmaceutical CDMO focused on oral thin-film and orally disintegrating tablet technologies, offering contract development and manufacturing services directly comparable to Cure's cGMP offering.
• MonoSol Rx (predecessor to Aquestive): Historical oral thin-film pioneer that evolved into Aquestive Therapeutics; the most established prior comparable platform business model for CUREFilm®-style licensing economics.

Broad incumbents

• LTS Lohmann Therapie-Systeme: Large, established transdermal and oral thin-film drug delivery CDMO with deep pharmaceutical partnerships; a broader incumbent that competes with Cure for contract manufacturing and licensing opportunities.
• Corium (now part of Angelini Pharma): Transdermal and oral drug delivery specialist acquired by Angelini Pharma; competes in adjacent drug-delivery categories and licenses platform technology to large pharma partners.
• Noven Pharmaceuticals (Hisamitsu subsidiary): Subsidiary of Hisamitsu Pharmaceutical specializing in transdermal drug delivery; a broad incumbent with FDA-approved products and established pharma licensing relationships in adjacent delivery formats.

Regional players

• Fertin Pharma: Danish oral delivery specialist (now part of Philip Morris International) developing oral thin-film and chewing-gum delivery formats for pharma and nicotine; competes globally in oral film technology but from a European base.

Emerging players

• ARx Pharma: Drug delivery technology company developing oral and transmucosal formulations; smaller-scale peer with overlapping technology platform targeting similar pharmaceutical reformulation partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/cure_pharma_

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cure Pharmaceutical